Oncocytic papillary carcinoma with lymphoid stroma (Warthin-like tumour) of the thyroid: a distinct entity with favourable prognosis
ABSTRACT Oncocytic papillary carcinoma with lymphoid stroma (Warthin-like tumour) of the thyroid: a distinct entity with favourable prognosis
Aims: We report the clinicopathological and immunohistochemical characteristics of 12 cases of a recently recognized entity, oncocytic papillary thyroid carcinoma (PC) with lymphoid stroma (Warthin-like tumour).
Methods and results: The cases were retrieved from the surgical pathology files of our departments. There were 11 female patients and one male patient; they ranged in age from 45 to 85 years (mean 64.2 years). The immunohistochemical profile demonstrated positivity of tumour cells for cytokeratins, thyroglobulin, Leu-M1 and anti-mitochondrial antigen. S100 protein-positive stromal dendritic/Langerhans cells were uniformly present. Polymerase chain reaction, in situ hybridization, and immunohistochemistry for Epstein–Barr virus (EBV) detection revealed no significant positive signal. MIB-1 labelling index was low, compatible with that of ‘classical’ PC.
Conclusions: Warthin-like tumour is a rare variant of PC, occurring predominantly in elderly women. Its histological features are distinct and well recognizable, differentiating this tumour from a more aggressive tall-cell variant of PC. The apparent indolent behaviour seems to be consistent with the presence of dendritic/Langerhans cells and with low proliferative activity. A possible role of EBV in pathogenesis of this lesion was not proven. Further studies are necessary to determine the prognosis and metastatic potential of this neoplasm.
- SourceAvailable from: Rosario Caltabiano
[Show abstract] [Hide abstract]
- "Molecular biology studies have shown that Warthin tumor-like PTC and conventional PTC share the same BRAF and RET mutations, supporting that the former is a morphological variant of the latter . However, whether Warthin tumor-like PTC should be considered a distinct clinico-pathologic entity with a favourable prognosis is still matter of debate     , because some authors have reported that about 30% of cases exhibit a tendency to lymph nodal metastases and extrathyroidal extension   . The possibility of PTC to undergo dedifferentiation is a rare but well-known event which has "
ABSTRACT: Warthin tumor-like papillary thyroid carcinoma is an uncommon variant of papillary thyroid carcinoma. We report a rare case of Warthin tumor-like variant of papillary thyroid carcinoma with a dedifferentiated component consisting of a solid tumor area composed of neoplastic cells with a spindle to tall cell morphology associated with marked nuclear pleomorphism, atypical mitoses, and foci of necrosis. Although our patient presented with a locally aggressive disease (T3 N1b Mo), she is disease-free without radioiodine therapy after a 23-month follow-up period. We emphasize that Warthin tumor-like papillary thyroid carcinoma, like other morphological variants of papillary carcinoma, may occasionally undergo dedifferentiation. As this component may be only focally detectable, we suggest an extensive sampling of all large-sized (>3 cm) papillary thyroid carcinoma. Recognition of any dedifferentiated component in a Warthin tumor-like papillary thyroid carcinoma should be reported, including its percentage, because it may reflect a more aggressive clinical course.Case Reports in Medicine 06/2010; 2010:495281. DOI:10.1155/2010/495281
- [Show abstract] [Hide abstract]
ABSTRACT: Hurthle cell papillary thyroid carcinoma is a variant of papillary thyroid carcinoma (PTC). Its pathologic and clinical significance has not been well documented. The authors studied the relative incidence of Hurthle cell PTC and the relationship of Hurthle cell PTC to other variants of thyroid carcinoma. Three hundred eighty consecutive cases of thyroid carcinoma were reviewed to identify cases with focal or extensive areas of Hurthle cell PTC, classic PTC, Hurthle cell carcinoma (ie, non-Hurthle cell PTC), and follicular carcinoma. In addition, the status of lymphoid infiltrate in the tumor, stromal invasion with desmoplastic reaction, vascular invasion, and distant and lymph node metastasis were noted by microscopic examination, review of clinical charts, or both. A total of 24 (HCs) and 42 PTCs with Hurthle cells were identified. The latter category was divided into pure Hurthle cell PTC or extensive Hurthle cell (HPTC) (28 cases) and PTC or Hurthle cell carcinoma with focal areas of Hurthle cell PTC (14 cases). The Hurthle cell PTC/Hurthle cell carcinoma ratio was lower than that of PTC/follicular carcinoma (39:289) (P = 0.001). Follicular or solid structures were present in all HPTCs. HPTCs were associated with frequent stromal intrathyroid and extrathyroid invasion, but they tended to have a lower rate of lymph node metastasis (8/28) compared with classic PTC with stromal invasion (108:200) (P = 0.12) and a lower rate of distant metastasis (2:28) compared with Hurthle cell carcinoma (15:24) (P = 0.02) or follicular carcinoma (13:39) (P= 0.04). Warthin-like Hurthle cell PTC (10 cases) was associated with extrathyroid invasion in five cases. In Hurthle cell PTC associated with tall cell variant (10 cases), areas of gradual transition between Hurthle cell PTC and tall cell variant were identified. The latter variant showed the highest rate of extrathyroid stromal and vascular invasion with distant metastasis and patient death compared with all Hurthle cell PTCs and classic PTCs. In conclusion, Hurthle cell PTC is frequently associated with tall cell variant. It has a higher potential for extrathyroid invasion than classic PTC and has vascular invasion and distant metastasis characteristics intermediate between those of classic PTC and Hurthle cell carcinoma with or follicular carcinoma. Hurthle cell PTC tends to show a greater likelihood of extrathyroid invasion when associated with Warthin-like features and tall cell variant PTC, and higher vascular invasion and distant metastasis when associated with tall cell variant.Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry 12/2004; 12(4):329-337. DOI:10.1097/00129039-200412000-00007 · 2.06 Impact Factor